Most Cancer Drugs Approved in Europe Lack High Clinical Benefit
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
An analysis found high clinical benefit in only 31% of 97 approved indications covering 63 cancer drugs in Europe from January 2022 to July 2026. Just nine drugs earned the top grade, while five manufacturers produced more than half of the 30 high-benefit indications.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu